Browse every story filed under this topic, curated from trusted publishers around the world.
With trial win, Novo Nordisk eyes adolescent diabetes approval for oral semaglutide
With the recent launch of Novo Nordisk’s Wegovy pill opening the oral GLP-1 market for obesity, the company has now unveiled positive results that could tee up an expansion in semaglutide’s inaugural diabetes indication.
Read full story →
MSD-backed Ray locks in $125m to back eye drug pipeline
Ray's MSD and Novo Holdings-backed Series B will shed light on the potential of the company's vision restoration gene therapy …
Amazon Just Put the Biggest Trade of the Decade on the Wrong Side—and Big Pharma Is Paying for It
Amazon’s new GLP-1 pricing is dragging Novo Nordisk and Eli Lilly stocks lower.
The Oral GLP-1 Tracker: Following the launch trajectories of Lilly’s Foundayo, Novo’s Wegovy pill
Fierce Pharma is launching the weekly Oral GLP-1 Tracker, leveraging analysts’ notes and IQVIA data to monitor prescription trends and …
You've seen all articles for #novo.
Check back
soon
for new stories.